Research Fraud “Fruitful” Area For Government Probes; AstraZeneca Brilinta Trial In Crosshairs
This article was originally published in The Pink Sheet Daily
Executive Summary
HHS Office of Inspector General’s Mary Riordan advises drug makers to analyze their speaker programs and consulting arrangements for possible kickback activities.